Does higher insulin suppress liver SHBG so that low SHBG indicates insulin resistance?

Sex hormone-binding globulin (SHBG) is primarily produced by the liver, and its circulating levels are highly sensitive to systemic metabolic shifts. Robust biochemical and clinical evidence supports the claim that elevated insulin levels directly suppress hepatic SHBG production, making low SHBG an excellent biomarker for underlying insulin resistance.

Mechanistic pathways

• Transcriptional repression: Elevated insulin and nutrient abundance suppress hepatocyte nuclear factor-4α (HNF-4α), which is the primary positive transcriptional regulator required to drive human SHBG gene expression.
• Lipogenic and inflammatory signaling: Hyperinsulinemia induces lipogenic transcription factors (like SREBP-1c) and de novo lipogenesis, which downregulates HNF-4α and allows repressive factors (such as COUP-TF1) to bind the SHBG promoter. Additionally, metabolic stress-induced inflammatory pathways (e.g., TNFα activating NF-κB) directly repress the HNF-4α promoter, halting SHBG mRNA synthesis.

Clinical and biomarker significance

• Surrogate for insulin resistance: Low circulating SHBG strongly correlates with elevated fasting insulin and HOMA-IR. In women (such as those with polycystic ovary syndrome), an SHBG level below 41.5 to 43.1 nmol/L serves as a highly sensitive marker of metabolic dysfunction, carrying a negative predictive value of 80% to 87% for ruling out significant insulin resistance.
• Predictive utility: This inverse relationship persists independently of BMI and body fat. Longitudinal trials demonstrate that low baseline SHBG levels precede and independently predict the future onset of type 2 diabetes. Furthermore, interventions that lower insulin levels and improve insulin sensitivity, such as GLP-1 receptor agonists, successfully restore circulating SHBG levels.

Bottom line

• Low serum SHBG is a highly reliable, clinically validated biomarker of hyperinsulinemia and insulin resistance, driven directly by insulin-induced hepatic lipogenesis and metabolic cascades that transcriptionally suppress SHBG synthesis in the liver.